Nucleoside analogues in the treatment of chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; EMTRICITABINE; ENTACAVIR; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; VIDARABINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNOMODULATION; LIVER FUNCTION; LIVER HISTOLOGY; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0033919380     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02103.x     Document Type: Conference Paper

References (36)

1. Weller IVD, Lok ASF, Mindel A et al. Randomised controlled trial of adenine arabinoside 5′-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 1985; 26: 745-51.
2. Ouzan D, Vicaut E, Ruet C, Trepo C. Meta-analysis of randomized controlled study of vidarabine phosphate in the treatment of HBe, HBV DNA+ chronic hepatitis. J. Hepatol. 1991; 13 (Suppl.): 220.
3. McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 1995; 336: 1099-105.
4. Gish RG, Lau JYN, Brooks L et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1-7.
5. Genovesi EV, Lamb L, Medina I et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 1998; 42: 3209-17.
6. Trepo C, Jezek P, Atkinson G, Boon R. Efficacy of famiciclovir in chronic hepatitis B. Results of a dose finding study. Hepatology 1996; 24: 188 (Abstract).
7. Chang TT, Leung NWY, Coulden S et al. Famciclovir (FCV) for the treatment of chronic hepatitis B (CHB): Results of one-year study in Asian patients. J. Hepatol. 1999; 30 (Suppl. 1): 114.
8. De Man RA, Habal F, Marcellin P et al. A randomized placebo-controlled study on the efficacy of 12-month famiciclovir treatment in patients with HBeAg+ hepatitis. J. Hepatol. 1999; 30 (Suppl. 1): 59.
9. Zoulim F, Tropo C. Drug therapy for chronic hepatitis B. Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 1998; 29: 151-68.
10. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
11. Heathcote EJ, Jeffers L, Wright T et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B. two placebo-controlled phase II studies. Hepatology 1998; 28: A317 (Abstract).
12. Gish RG, Leung NWY, Wright TL et al. Anti-hepatitis B virus (HBV) activity and pharmacokinetics of FTC in a 2-month trial in HBV-infected patients. Gastroenterology 1999; 116: A1216 (Abstract).
13. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 1998; 102: 968-75.
14. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
15. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
16. Dienstag J, Schiff E, Wright T et al. Lamivudine treatment for one year in previously untreated US hepatitis B patients: Histologic improvement and hepatitis e-antigen (HBeAg) seroconversion. Gastroenterology 1998; 114: A1235 (Abstract).
17. Heathcote J, Schalm SW, Cianciara J et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection. J. Hepatol. 1998; 28 (Suppl. 1): 43.
18. Schiff E, Karayalcin S, Grimm I et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998; 28: A388 (Abstract).
19. Schiff E, Cianciara J, Kowdley K et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. Hepatology 1998; 28: A164 (Abstract).
20. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-7.
21. Chang TT, Lai CL, Liaw YF et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine. Hepatology 1999; 29.
22. Liaw YF, Lai CL, Leung NWY et al. Two year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicentre study in Asian. Gastroenterology 1998; 114 (Suppl. 2): 1289.
23. Leung NWY, Lai CL, Chang TT et al. Three year lamivudine in chronic HBV. J. Hepatol. 1999; 30 (Suppl. 1): 59.
24. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seeroconversion during lamivudine therapy in patients with chronic hepatitis B (Asian Hepatitis Lamivudine Trial Group). Hepatology 1999; 30: 770-4.
25. Yao G, Wang B, Cui Z, Yao J, Minde Z. Long-term efficacy of lamivudine in the treatment of patients with chronic hepatitis B virus infection: A multicentre randomised, double blind, placebo-controlled trial. Gastroenterology 1999; 116: A848 (Abstract).
26. Leung N, Wu PC, Tsang S et al. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine. Hepatology 1998; 28: A489 (Abstract).
27. Goodman Z, Dhillon AP, Wu PC et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J. Hepatol. 1999; 30 (Suppl. 1): 59.
28. Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol. 1999; 30: 743-8.
29. Tassopoulos NC, Volpes R, Pastore G et al. Efficiacy of lamivudine in patients with hepatitis B e antigen negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96.
30. Tassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J. Hepatol. 1999; 30 (Suppl. 1): 117.
31. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
32. Honkoop P, de Man RA, Niesters HGM, Schalm SW Clinical impact of lamivudine resistance in chronic hepatitis B. J. Hepatol. 1998; 29: 510-14.
33. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
34. Atkin M, Hunt CM, Brown N et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 1998; 28: A319 (Abstract).
35. Mutimer D, Naoumov N, Honkoop P et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon resistant chronic hepatitis B infection: Results of a pilot study. J. Hepatol. 1998; 28: 923-9.
36. Liaw YF, Chien RN. Case report: Dramatic response to lamivudine therapy following corticosteriod priming in chronic hepatitis B. J. Gastroenterol. Hepatol. 1999; 14: 804-6.